UTokyo Innovation Platform
VC Fund
Tokyo, Japan
UTokyo Innovation Platform is a VC fund in Tokyo focused on Biotechnology and Medical. The University of Tokyo IPC is a company responsible for expanding the innovation ecosystem. Accelerate global innovation from the University of Tokyo through three activities: start-up support, investment business, and corporate innovation support.
- Total investments:
- 85
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries UTokyo Innovation Platform invests in
Stages UTokyo Innovation Platform invests in
Countries UTokyo Innovation Platform invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 14 (16%)
- Medical 10 (12%)
- Manufacturing 10 (12%)
- Software 7 (8%)
- Health Care 7 (8%)
Stage
- Series A 17 (20%)
- Funding Round 15 (18%)
- Seed 14 (16%)
- Series B 13 (15%)
- Series D 3 (4%)
Country
- Japan 49 (58%)
- United States 4 (5%)
- United Kingdom 2 (2%)
- Taiwan 1 (1%)
- Ethiopia 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Makoto Ohori
Partner | Chief Investment Officer, Life Science
|
Partner | Chief Investment Officer, Life Science | Total investments: 5 | Find email | |
|
Hiroho Fukuda
Auditor
|
Auditor | Total investments: 0 | Find email | |
Katsuhiko Oizumi
Founder, President and CEO
|
Founder, President and CEO | Total investments: 2 | Find email | |
Kazuhiko Kakehi
Partner,Academic Co-Innovation
|
Partner,Academic Co-Innovation | Total investments: 0 | Find email | |
Kei Furukawa
Manager,Investment and Business Development
|
Manager,Investment and Business Development | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CORE Biomedicine
|
CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology. | $21M / Series A / Jul 28, 2026 | |
Dodai
|
Dodai manufactures and assembles the electric motorcycles. | $8M / Series A / Apr 28, 2026 | |
Storm Therapeutics
|
Targeting pathways that modify RNA to deliver novel cancer therapeutics. | $56M / Series C / Apr 16, 2026 | |
Logomix
|
Logomix Inc is a mammalian cellular genome architect startup. Logomix proprietary platform, Geno-Writing™, technology integrates large-scale (Mb) human genome-writing technologies and providing genetically architected versatile human cells and/or downsized cells and microbes for drug development and cell & gene therapy area.Majority ofthe cell engineering companies are currently focused on optimization of gene clusters by automatic high throughput system however, Logomix’s Geno-Writing™ provides the required tools for dealing with mammalian or complex genomes. Logomix works with partners by providing new biology-based solutions to co-create business and social values on Geno-Writing™ platform Current Focus Area includes: 1. Human Health & Therapeutics 2. Biomaterials & Chemicals 3. Agriculture & EnvironmentLogomix has 11 ongoing collaborative research partnerships. Currently Logomix is specifically looking for industry partners to address unmet needs in neurodegenerative disease areas. | $18.8M / Jul 30, 2025 | |
Instalimb
|
Instalimb is the world's first 3D printing prosthesis business. It uses advanced 3D printing, 3D-CAD, and machine-learning technologies to produce affordable, high-quality prosthetic legs. By integrating these tools into its manufacturing process, the company delivers reliable and low-cost 3D-printed prosthetics and orthotics. | $7.3M / Series B / Mar 26, 2025 | |
|
Instalimb
|
Instalimb is the world's first 3D printing prosthesis business. It uses advanced 3D printing, 3D-CAD, and machine-learning technologies to produce affordable, high-quality prosthetic legs. By integrating these tools into its manufacturing process, the company delivers reliable and low-cost 3D-printed prosthetics and orthotics. | $7.3M / Series B / Mar 26, 2025 | |
Ubitus
|
Established in 2013. The headquarter is located in Tokyo. Supported by R&D center in Taipei. Ubitus is a technology leader in deploying cloud-enabled rich media services, offers major game companies and telcos the world’s best cloud gaming solution. With the same innovative GameCloud technology, Ubitus is able to stream metaverse content onmulti-devices for platform operators and digital content developers. | Venture - Series Unknown / Feb 26, 2025 | |
Leading Mark
|
Leading Mark, a rising human resources startup in Japan. Leading Mark is branching out into mid-career and international hiring. It currently has a one-man team in China working to bring the top Japanese-speaking Chinese students to domestic companies. He also touts his startup’s focus on the average job seeker. “We want to make sure that the usersget the info that he or she needs the most,” he says. Large scale, legacy players can sometimes prioritize the needs of the hiring company, and their commission, over the needs of applicants themselves. This leads to frustration and short-circuited careers. | $10.6M / Venture - Series Unknown / Feb 05, 2025 | |
Issin
|
Issin manufactures bath mats that can measure weight and automatically record daily weight changes on your smartphone. | $2.8M / Venture - Series Unknown / Feb 04, 2025 | |
BlueWX
|
BlueWX is a software company that develops predictive content services that supports in forecasting, and weather analysis. | $774.6K / Series A / Jan 27, 2025 | |
| See all 85 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does UTokyo Innovation Platform invest in?
UTokyo Innovation Platform invests primarily in Biotechnology, Medical and Manufacturing startups, most often at Series A and Funding Round stage. Most of the 85 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact UTokyo Innovation Platform?
Public channels for UTokyo Innovation Platform include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at UTokyo Innovation Platform?
The team at UTokyo Innovation Platform includes Makoto Ohori (Partner | Chief Investment Officer, Life Science), Hiroho Fukuda (Auditor) and Katsuhiko Oizumi (Founder, President and CEO), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
